can 508 profile

CAN 508: has antiangiogenic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

CAN-508 : A member of the class of pyrazoles that is 1H-pyrazole substituted by amino, (4-hydroxyphenyl)diazenyl, and amino groups at positions 3, 4 and 5, respectively. It is a CDK9 inhibitor (IC50 = 0.35 muM) with 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135398514
CHEMBL ID	215205
CHEMBL ID	1823556
CHEBI ID	42356
SCHEMBL ID	3310182
SCHEMBL ID	922292
SCHEMBL ID	12589685
MeSH ID	M0569491

Synonym
4-[(e)-(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol
F18 ,
bdbm12028
4-[(e)-2-(3,5-diamino-1h-pyrazol-4-yl)diazen-1-yl]phenol
can508
2CLX
4-arylazo-3,5-diamino-1h-pyrazole 31b
cdk9 inhibitor ii
4-(3,5-diamino-1h-pyrazol-4-ylazo)-phenol
AKOS000272941
can-508
DB07731
CHEMBL215205 ,
HMS3229D19
nsc-741614
nsc741614
3,5-diamino-4-(4-hydroxyphenyl)azopyrazole
bdbm50352019
chembl1823556
zg0o47k626 ,
unii-zg0o47k626
phenol, 4-((3,5-diamino-1h-pyrazol-4-yl)azo)-
phenol, 4-(2-(3,5-diamino-1h-pyrazol-4-yl)diazenyl)-
3TNH
140651-18-9
3TN8
SCHEMBL3310182
SCHEMBL922292
SCHEMBL12589685
phenol, 4-[(3,5-diamino-1h-pyrazol-4-yl)azo]-
1649984-48-4
J-007412
4-[(z)-(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol
4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol
4-[2-(3,5-diamino-1h-pyrazol-4-yl)diazen-1-yl]phenol
Q27096948
can-508;can508;cdk9 inhibitor ii
can 508
HY-100429
phenol, 4-[2-(3,5-diamino-1h-pyrazol-4-yl)diazenyl]-
CS-0018885
NCGC00388443-01
4-((3,5-diamino-1h-pyrazol-4-yl)diazenyl)phenol
DTXSID90901895
noname_1070
MS-23203
4-[(3,5-diamino-1h-pyrazol-4-yl)azo]-phenol
cay10574
(e)-4-((3,5-diamino-1h-pyrazol-4-yl)diazenyl)phenol
bdbm50455463
cay 10574
cay-10574
CHEBI:42356

Excerpt	Reference
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)

Role	Description
angiogenesis inhibitor	An agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of cyclin-dependent kinase (EC 2.7.11.22).
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrazoles
phenols	Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
aromatic amine	An amino compound in which the amino group is linked directly to an aromatic system.
monoazo compound	Compounds containing single -N=N- group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Cyclin-dependent kinase 9	Homo sapiens (human)	IC50 (µMol)	0.7400	0.7400	0.7400	0.7400	AID977608
Cyclin-T1	Homo sapiens (human)	IC50 (µMol)	17.4050	0.0010	0.5585	8.0000	AID1194742; AID1375009; AID1689408; AID1796840; AID272423
Cyclin-T1	Homo sapiens (human)	Ki	0.3500	0.0030	0.2768	0.7900	AID723735
G2/mitotic-specific cyclin-B2	Homo sapiens (human)	IC50 (µMol)	44.0000	0.0025	1.8172	10.0000	AID272419
G1/S-specific cyclin-E2	Homo sapiens (human)	IC50 (µMol)	11.7500	0.0010	1.7394	10.0000	AID272408; AID272418
G1/S-specific cyclin-E2	Homo sapiens (human)	Ki	13.3000	0.5400	0.5400	0.5400	AID272417
Cyclin-dependent kinase 1	Homo sapiens (human)	IC50 (µMol)	28.0538	0.0004	1.3452	10.0000	AID1194739; AID1796840; AID1800495; AID272419
Cyclin-dependent kinase 4	Homo sapiens (human)	IC50 (µMol)	23.3615	0.0006	0.5706	10.0000	AID1194740; AID1796840; AID1800495; AID272421
G2/mitotic-specific cyclin-B1	Homo sapiens (human)	IC50 (µMol)	32.6062	0.0013	1.4518	10.0000	AID1194739; AID1796840; AID272419
Cyclin-A2	Homo sapiens (human)	IC50 (µMol)	31.8688	0.0004	1.0339	10.0000	AID1375008; AID1796840; AID272420
Cyclin-A2	Homo sapiens (human)	Ki	69.0000	0.0010	0.7007	5.0000	AID723734
Ribosomal protein S6 kinase beta-1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0004	0.9046	10.0000	AID272483
G1/S-specific cyclin-D1	Homo sapiens (human)	IC50 (µMol)	24.9812	0.0006	0.5479	9.5000	AID1194740; AID1796840; AID272421
G1/S-specific cyclin-E1	Homo sapiens (human)	IC50 (µMol)	23.6350	0.0010	1.0404	10.0000	AID1194735; AID1689407; AID1796840; AID272408; AID272418
G1/S-specific cyclin-E1	Homo sapiens (human)	Ki	13.3000	0.0005	0.5633	1.4850	AID272417
Cyclin-dependent kinase 2	Homo sapiens (human)	IC50 (µMol)	24.8412	0.0004	1.0444	10.0000	AID1194735; AID1375008; AID1689407; AID1796840; AID1800495; AID272408; AID272418; AID272420
Cyclin-dependent kinase 2	Homo sapiens (human)	Ki	41.1500	0.0005	0.6427	5.0000	AID272417; AID723734
Cyclin-dependent kinase 7	Homo sapiens (human)	IC50 (µMol)	25.2846	0.0001	0.9106	9.2000	AID1194741; AID1796840; AID1800495; AID272422
Cyclin-dependent kinase 9	Homo sapiens (human)	IC50 (µMol)	17.3906	0.0010	0.6236	8.0000	AID1194742; AID1375009; AID1689408; AID1796840; AID1800495; AID272423; AID617519
Cyclin-dependent kinase 9	Homo sapiens (human)	Ki	0.3500	0.0030	0.2482	0.7900	AID723735
Cyclin-H	Homo sapiens (human)	IC50 (µMol)	28.1062	0.0005	1.0823	9.2000	AID1194741; AID1796840; AID272422
Cyclin-A1	Homo sapiens (human)	IC50 (µMol)	69.0000	0.0005	1.4715	10.0000	AID272420
Cyclin-A1	Homo sapiens (human)	Ki	69.0000	0.0040	0.1480	0.2500	AID723734
G2/mitotic-specific cyclin-B3	Homo sapiens (human)	IC50 (µMol)	44.0000	0.0025	1.8172	10.0000	AID272419
Ribosomal protein S6 kinase beta-2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0007	2.5038	10.0000	AID272483
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of cyclin-dependent protein serine/threonine kinase activity	Cyclin-T1	Homo sapiens (human)
transcription by RNA polymerase II	Cyclin-T1	Homo sapiens (human)
response to xenobiotic stimulus	Cyclin-T1	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Cyclin-T1	Homo sapiens (human)
positive regulation by host of viral transcription	Cyclin-T1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-T1	Homo sapiens (human)
cell division	Cyclin-T1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cyclin-T1	Homo sapiens (human)
positive regulation of DNA-templated transcription, elongation	Cyclin-T1	Homo sapiens (human)
in utero embryonic development	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
spindle assembly involved in female meiosis I	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
G2/MI transition of meiotic cell cycle	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
regulation of growth	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
T cell homeostasis	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
thymus development	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cell division	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
mitotic cell cycle phase transition	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G1/S-specific cyclin-E2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E2	Homo sapiens (human)
telomere maintenance	G1/S-specific cyclin-E2	Homo sapiens (human)
DNA replication initiation	G1/S-specific cyclin-E2	Homo sapiens (human)
homologous chromosome pairing at meiosis	G1/S-specific cyclin-E2	Homo sapiens (human)
regulation of protein localization	G1/S-specific cyclin-E2	Homo sapiens (human)
cell division	G1/S-specific cyclin-E2	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
microtubule cytoskeleton organization	Cyclin-dependent kinase 1	Homo sapiens (human)
DNA replication	Cyclin-dependent kinase 1	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 1	Homo sapiens (human)
chromatin remodeling	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 1	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 1	Homo sapiens (human)
apoptotic process	Cyclin-dependent kinase 1	Homo sapiens (human)
DNA damage response	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic nuclear membrane disassembly	Cyclin-dependent kinase 1	Homo sapiens (human)
centrosome cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
pronuclear fusion	Cyclin-dependent kinase 1	Homo sapiens (human)
response to xenobiotic stimulus	Cyclin-dependent kinase 1	Homo sapiens (human)
response to toxic substance	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of gene expression	Cyclin-dependent kinase 1	Homo sapiens (human)
negative regulation of gene expression	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of Schwann cell differentiation	Cyclin-dependent kinase 1	Homo sapiens (human)
response to amine	Cyclin-dependent kinase 1	Homo sapiens (human)
response to activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cell migration	Cyclin-dependent kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Cyclin-dependent kinase 1	Homo sapiens (human)
chromosome condensation	Cyclin-dependent kinase 1	Homo sapiens (human)
epithelial cell differentiation	Cyclin-dependent kinase 1	Homo sapiens (human)
animal organ regeneration	Cyclin-dependent kinase 1	Homo sapiens (human)
protein localization to kinetochore	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of protein import into nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of circadian rhythm	Cyclin-dependent kinase 1	Homo sapiens (human)
negative regulation of apoptotic process	Cyclin-dependent kinase 1	Homo sapiens (human)
response to ethanol	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of DNA replication	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of embryonic development	Cyclin-dependent kinase 1	Homo sapiens (human)
response to cadmium ion	Cyclin-dependent kinase 1	Homo sapiens (human)
response to copper ion	Cyclin-dependent kinase 1	Homo sapiens (human)
symbiont entry into host cell	Cyclin-dependent kinase 1	Homo sapiens (human)
fibroblast proliferation	Cyclin-dependent kinase 1	Homo sapiens (human)
rhythmic process	Cyclin-dependent kinase 1	Homo sapiens (human)
response to axon injury	Cyclin-dependent kinase 1	Homo sapiens (human)
cell division	Cyclin-dependent kinase 1	Homo sapiens (human)
ventricular cardiac muscle cell development	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of mitotic sister chromatid segregation	Cyclin-dependent kinase 1	Homo sapiens (human)
protein-containing complex assembly	Cyclin-dependent kinase 1	Homo sapiens (human)
cellular response to hydrogen peroxide	Cyclin-dependent kinase 1	Homo sapiens (human)
ERK1 and ERK2 cascade	Cyclin-dependent kinase 1	Homo sapiens (human)
cellular response to organic cyclic compound	Cyclin-dependent kinase 1	Homo sapiens (human)
Golgi disassembly	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of protein localization to nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of attachment of mitotic spindle microtubules to kinetochore	Cyclin-dependent kinase 1	Homo sapiens (human)
microtubule cytoskeleton organization involved in mitosis	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transport	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Cyclin-dependent kinase 1	Homo sapiens (human)
protein deubiquitination	Cyclin-dependent kinase 1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Cyclin-dependent kinase 4	Homo sapiens (human)
response to xenobiotic stimulus	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 4	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
positive regulation of fibroblast proliferation	Cyclin-dependent kinase 4	Homo sapiens (human)
cell division	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of transcription initiation by RNA polymerase II	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of type B pancreatic cell proliferation	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to lipopolysaccharide	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to interleukin-4	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristate	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to ionomycin	Cyclin-dependent kinase 4	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 4	Homo sapiens (human)
G2/M transition of mitotic cell cycle	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
in utero embryonic development	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
mitotic spindle organization	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
mitotic metaphase chromosome alignment	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
positive regulation of mitotic cell cycle	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
positive regulation of fibroblast proliferation	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cell division	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochore	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
regulation of mitotic cell cycle spindle assembly checkpoint	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transport	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
mitotic cell cycle phase transition	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-A2	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-A2	Homo sapiens (human)
regulation of DNA replication	Cyclin-A2	Homo sapiens (human)
DNA-templated transcription	Cyclin-A2	Homo sapiens (human)
Ras protein signal transduction	Cyclin-A2	Homo sapiens (human)
animal organ regeneration	Cyclin-A2	Homo sapiens (human)
response to glucagon	Cyclin-A2	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Cyclin-A2	Homo sapiens (human)
post-translational protein modification	Cyclin-A2	Homo sapiens (human)
cellular response to leptin stimulus	Cyclin-A2	Homo sapiens (human)
cell cycle G1/S phase transition	Cyclin-A2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cyclin-A2	Homo sapiens (human)
positive regulation of fibroblast proliferation	Cyclin-A2	Homo sapiens (human)
cell division	Cyclin-A2	Homo sapiens (human)
cellular response to cocaine	Cyclin-A2	Homo sapiens (human)
cellular response to luteinizing hormone stimulus	Cyclin-A2	Homo sapiens (human)
cellular response to estradiol stimulus	Cyclin-A2	Homo sapiens (human)
cellular response to hypoxia	Cyclin-A2	Homo sapiens (human)
cellular response to nitric oxide	Cyclin-A2	Homo sapiens (human)
cochlea development	Cyclin-A2	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Cyclin-A2	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Cyclin-A2	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	Cyclin-A2	Homo sapiens (human)
mitotic cell cycle phase transition	Cyclin-A2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
behavioral fear response	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
skeletal muscle contraction	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
apoptotic process	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
signal transduction	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
germ cell development	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
long-term memory	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to xenobiotic stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to mechanical stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to toxic substance	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to glucose	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
skeletal muscle atrophy	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to electrical stimulus involved in regulation of muscle adaptation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cell migration	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to nutrient levels	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to nutrient	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
TOR signaling	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to lipopolysaccharide	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to testosterone	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to glucagon	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to tumor necrosis factor	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
negative regulation of apoptotic process	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to L-leucine	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
long-chain fatty acid import into cell	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to ethanol	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of translation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of mitotic cell cycle	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of translational initiation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
regulation of glucose import	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of skeletal muscle tissue growth	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
modulation of chemical synaptic transmission	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to type II interferon	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to growth factor stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to dexamethasone stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of TORC1 signaling	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to insulin stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	G1/S-specific cyclin-D1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	G1/S-specific cyclin-D1	Homo sapiens (human)
re-entry into mitotic cell cycle	G1/S-specific cyclin-D1	Homo sapiens (human)
positive regulation of protein phosphorylation	G1/S-specific cyclin-D1	Homo sapiens (human)
DNA damage response	G1/S-specific cyclin-D1	Homo sapiens (human)
lactation	G1/S-specific cyclin-D1	Homo sapiens (human)
response to xenobiotic stimulus	G1/S-specific cyclin-D1	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	G1/S-specific cyclin-D1	Homo sapiens (human)
Wnt signaling pathway	G1/S-specific cyclin-D1	Homo sapiens (human)
neuron differentiation	G1/S-specific cyclin-D1	Homo sapiens (human)
negative regulation of epithelial cell differentiation	G1/S-specific cyclin-D1	Homo sapiens (human)
endoplasmic reticulum unfolded protein response	G1/S-specific cyclin-D1	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	G1/S-specific cyclin-D1	Homo sapiens (human)
mammary gland epithelial cell proliferation	G1/S-specific cyclin-D1	Homo sapiens (human)
positive regulation of mammary gland epithelial cell proliferation	G1/S-specific cyclin-D1	Homo sapiens (human)
negative regulation of neuron apoptotic process	G1/S-specific cyclin-D1	Homo sapiens (human)
response to leptin	G1/S-specific cyclin-D1	Homo sapiens (human)
fat cell differentiation	G1/S-specific cyclin-D1	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	G1/S-specific cyclin-D1	Homo sapiens (human)
cell division	G1/S-specific cyclin-D1	Homo sapiens (human)
mammary gland alveolus development	G1/S-specific cyclin-D1	Homo sapiens (human)
response to UV-A	G1/S-specific cyclin-D1	Homo sapiens (human)
liver regeneration	G1/S-specific cyclin-D1	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	G1/S-specific cyclin-D1	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G1/S-specific cyclin-D1	Homo sapiens (human)
protein phosphorylation	G1/S-specific cyclin-E1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	G1/S-specific cyclin-E1	Homo sapiens (human)
telomere maintenance	G1/S-specific cyclin-E1	Homo sapiens (human)
DNA replication initiation	G1/S-specific cyclin-E1	Homo sapiens (human)
homologous chromosome pairing at meiosis	G1/S-specific cyclin-E1	Homo sapiens (human)
Wnt signaling pathway	G1/S-specific cyclin-E1	Homo sapiens (human)
regulation of protein localization	G1/S-specific cyclin-E1	Homo sapiens (human)
cell division	G1/S-specific cyclin-E1	Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferation	G1/S-specific cyclin-E1	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G1/S-specific cyclin-E1	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 2	Homo sapiens (human)
chromatin remodeling	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
potassium ion transport	Cyclin-dependent kinase 2	Homo sapiens (human)
centriole replication	Cyclin-dependent kinase 2	Homo sapiens (human)
Ras protein signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Cyclin-dependent kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of heterochromatin formation	Cyclin-dependent kinase 2	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiation	Cyclin-dependent kinase 2	Homo sapiens (human)
telomere maintenance in response to DNA damage	Cyclin-dependent kinase 2	Homo sapiens (human)
post-translational protein modification	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome duplication	Cyclin-dependent kinase 2	Homo sapiens (human)
cell division	Cyclin-dependent kinase 2	Homo sapiens (human)
meiotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular response to nitric oxide	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular senescence	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 2	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription by RNA polymerase II	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription initiation at RNA polymerase II promoter	Cyclin-dependent kinase 7	Homo sapiens (human)
snRNA transcription by RNA polymerase II	Cyclin-dependent kinase 7	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 7	Homo sapiens (human)
protein stabilization	Cyclin-dependent kinase 7	Homo sapiens (human)
cell division	Cyclin-dependent kinase 7	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 7	Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 7	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 7	Homo sapiens (human)
regulation of mitotic cell cycle	Cyclin-dependent kinase 9	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 9	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of DNA repair	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription initiation at RNA polymerase II promoter	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
cell population proliferation	Cyclin-dependent kinase 9	Homo sapiens (human)
replication fork processing	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of mRNA 3'-end processing	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation by host of viral transcription	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of muscle cell differentiation	Cyclin-dependent kinase 9	Homo sapiens (human)
nucleus localization	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 9	Homo sapiens (human)
cellular response to cytokine stimulus	Cyclin-dependent kinase 9	Homo sapiens (human)
negative regulation of protein localization to chromatin	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation of protein localization to chromatin	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation-coupled chromatin remodeling	Cyclin-dependent kinase 9	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cyclin-H	Homo sapiens (human)
transcription initiation at RNA polymerase II promoter	Cyclin-H	Homo sapiens (human)
protein stabilization	Cyclin-H	Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycle	Cyclin-H	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	Cyclin-H	Homo sapiens (human)
male meiosis I	Cyclin-A1	Homo sapiens (human)
spermatogenesis	Cyclin-A1	Homo sapiens (human)
cell division	Cyclin-A1	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	Cyclin-A1	Homo sapiens (human)
mitotic cell cycle phase transition	Cyclin-A1	Homo sapiens (human)
cell division	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
meiotic cell cycle	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
mitotic cell cycle phase transition	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
translation	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
signal transduction	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
TOR signaling	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
positive regulation of translational initiation	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Cyclin-T1	Homo sapiens (human)
DNA binding	Cyclin-T1	Homo sapiens (human)
chromatin binding	Cyclin-T1	Homo sapiens (human)
protein binding	Cyclin-T1	Homo sapiens (human)
protein kinase binding	Cyclin-T1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	Cyclin-T1	Homo sapiens (human)
RNA polymerase binding	Cyclin-T1	Homo sapiens (human)
7SK snRNA binding	Cyclin-T1	Homo sapiens (human)
DNA-binding transcription factor binding	Cyclin-T1	Homo sapiens (human)
molecular condensate scaffold activity	Cyclin-T1	Homo sapiens (human)
protein binding	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cadherin binding	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
protein binding	G1/S-specific cyclin-E2	Homo sapiens (human)
protein kinase binding	G1/S-specific cyclin-E2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G1/S-specific cyclin-E2	Homo sapiens (human)
virus receptor activity	Cyclin-dependent kinase 1	Homo sapiens (human)
chromatin binding	Cyclin-dependent kinase 1	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 1	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 1	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 1	Homo sapiens (human)
Hsp70 protein binding	Cyclin-dependent kinase 1	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 4	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 4	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 4	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 4	Homo sapiens (human)
patched binding	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
protein binding	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
protein kinase binding	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
ubiquitin-like protein ligase binding	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
protein binding	Cyclin-A2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	Cyclin-A2	Homo sapiens (human)
protein kinase binding	Cyclin-A2	Homo sapiens (human)
protein domain specific binding	Cyclin-A2	Homo sapiens (human)
protein kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
PDZ domain binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
peptide binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
identical protein binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein phosphatase 2A binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
transcription corepressor activity	G1/S-specific cyclin-D1	Homo sapiens (human)
protein kinase activity	G1/S-specific cyclin-D1	Homo sapiens (human)
protein binding	G1/S-specific cyclin-D1	Homo sapiens (human)
enzyme binding	G1/S-specific cyclin-D1	Homo sapiens (human)
protein kinase binding	G1/S-specific cyclin-D1	Homo sapiens (human)
histone deacetylase binding	G1/S-specific cyclin-D1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	G1/S-specific cyclin-D1	Homo sapiens (human)
proline-rich region binding	G1/S-specific cyclin-D1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G1/S-specific cyclin-D1	Homo sapiens (human)
protein binding	G1/S-specific cyclin-E1	Homo sapiens (human)
kinase activity	G1/S-specific cyclin-E1	Homo sapiens (human)
protein kinase binding	G1/S-specific cyclin-E1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G1/S-specific cyclin-E1	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
magnesium ion binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 2	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein domain specific binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 7	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 7	Homo sapiens (human)
ATP-dependent activity, acting on DNA	Cyclin-dependent kinase 7	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription coactivator binding	Cyclin-dependent kinase 9	Homo sapiens (human)
DNA binding	Cyclin-dependent kinase 9	Homo sapiens (human)
chromatin binding	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation factor activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 9	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 9	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein kinase binding	Cyclin-dependent kinase 9	Homo sapiens (human)
7SK snRNA binding	Cyclin-dependent kinase 9	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
RNA polymerase II general transcription initiation factor activity	Cyclin-H	Homo sapiens (human)
protein binding	Cyclin-H	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	Cyclin-H	Homo sapiens (human)
protein binding	Cyclin-A1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	Cyclin-A1	Homo sapiens (human)
protein binding	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
protein kinase activity	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
peptide binding	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleolus	Cyclin-T1	Homo sapiens (human)
nucleus	Cyclin-T1	Homo sapiens (human)
nucleus	Cyclin-T1	Homo sapiens (human)
nucleoplasm	Cyclin-T1	Homo sapiens (human)
cytosol	Cyclin-T1	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-T1	Homo sapiens (human)
P-TEFb complex	Cyclin-T1	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cytosol	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
microtubule cytoskeleton	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
membrane	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cytoplasm	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
nucleus	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
nucleoplasm	G1/S-specific cyclin-E2	Homo sapiens (human)
cytosol	G1/S-specific cyclin-E2	Homo sapiens (human)
cyclin E2-CDK2 complex	G1/S-specific cyclin-E2	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E2	Homo sapiens (human)
cytoplasm	G1/S-specific cyclin-E2	Homo sapiens (human)
centrosome	G1/S-specific cyclin-E2	Homo sapiens (human)
cyclin E1-CDK2 complex	G1/S-specific cyclin-E2	Homo sapiens (human)
mitochondrial matrix	Cyclin-dependent kinase 1	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 1	Homo sapiens (human)
mitochondrion	Cyclin-dependent kinase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Cyclin-dependent kinase 1	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 1	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 1	Homo sapiens (human)
spindle microtubule	Cyclin-dependent kinase 1	Homo sapiens (human)
membrane	Cyclin-dependent kinase 1	Homo sapiens (human)
midbody	Cyclin-dependent kinase 1	Homo sapiens (human)
extracellular exosome	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic spindle	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin A1-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin A2-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin B1-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleolus	Cyclin-dependent kinase 4	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 4	Homo sapiens (human)
bicellular tight junction	Cyclin-dependent kinase 4	Homo sapiens (human)
nuclear membrane	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin D1-CDK4 complex	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin D2-CDK4 complex	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin D3-CDK4 complex	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 4	Homo sapiens (human)
chromatin	Cyclin-dependent kinase 4	Homo sapiens (human)
transcription regulator complex	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 4	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 4	Homo sapiens (human)
mitochondrial matrix	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
spindle pole	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
nucleus	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
nucleoplasm	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cytoplasm	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cytosol	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
membrane	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cyclin B1-CDK1 complex	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
outer kinetochore	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
cytoplasm	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
nucleus	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B1	Homo sapiens (human)
female pronucleus	Cyclin-A2	Homo sapiens (human)
male pronucleus	Cyclin-A2	Homo sapiens (human)
nucleus	Cyclin-A2	Homo sapiens (human)
nucleoplasm	Cyclin-A2	Homo sapiens (human)
cytoplasm	Cyclin-A2	Homo sapiens (human)
cytosol	Cyclin-A2	Homo sapiens (human)
cyclin A2-CDK1 complex	Cyclin-A2	Homo sapiens (human)
cyclin A2-CDK2 complex	Cyclin-A2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-A2	Homo sapiens (human)
nucleus	Cyclin-A2	Homo sapiens (human)
centrosome	Cyclin-A2	Homo sapiens (human)
cytoplasm	Cyclin-A2	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
mitochondrion	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
mitochondrial outer membrane	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cell surface	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
neuron projection	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
perinuclear region of cytoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
postsynapse	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
glutamatergic synapse	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-D1	Homo sapiens (human)
nucleoplasm	G1/S-specific cyclin-D1	Homo sapiens (human)
cytosol	G1/S-specific cyclin-D1	Homo sapiens (human)
bicellular tight junction	G1/S-specific cyclin-D1	Homo sapiens (human)
nuclear membrane	G1/S-specific cyclin-D1	Homo sapiens (human)
cyclin D1-CDK4 complex	G1/S-specific cyclin-D1	Homo sapiens (human)
cyclin D1-CDK6 complex	G1/S-specific cyclin-D1	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	G1/S-specific cyclin-D1	Homo sapiens (human)
transcription repressor complex	G1/S-specific cyclin-D1	Homo sapiens (human)
centrosome	G1/S-specific cyclin-D1	Homo sapiens (human)
cytoplasm	G1/S-specific cyclin-D1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-D1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E1	Homo sapiens (human)
nucleoplasm	G1/S-specific cyclin-E1	Homo sapiens (human)
cytosol	G1/S-specific cyclin-E1	Homo sapiens (human)
cyclin E1-CDK2 complex	G1/S-specific cyclin-E1	Homo sapiens (human)
centrosome	G1/S-specific cyclin-E1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E1	Homo sapiens (human)
cytoplasm	G1/S-specific cyclin-E1	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 2	Homo sapiens (human)
condensed chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
X chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
Y chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
male germ cell nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nuclear envelope	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
endosome	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 2	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 2	Homo sapiens (human)
Cajal body	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 2	Homo sapiens (human)
transcription regulator complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 7	Homo sapiens (human)
fibrillar center	Cyclin-dependent kinase 7	Homo sapiens (human)
male germ cell nucleus	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 7	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 7	Homo sapiens (human)
plasma membrane	Cyclin-dependent kinase 7	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription factor TFIIH core complex	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription factor TFIIH holo complex	Cyclin-dependent kinase 7	Homo sapiens (human)
CAK-ERCC2 complex	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription factor TFIIK complex	Cyclin-dependent kinase 7	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 9	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 9	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 9	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-dependent kinase 9	Homo sapiens (human)
membrane	Cyclin-dependent kinase 9	Homo sapiens (human)
PML body	Cyclin-dependent kinase 9	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation factor complex	Cyclin-dependent kinase 9	Homo sapiens (human)
P-TEFb complex	Cyclin-dependent kinase 9	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-H	Homo sapiens (human)
nucleoplasm	Cyclin-H	Homo sapiens (human)
transcription factor TFIIH core complex	Cyclin-H	Homo sapiens (human)
transcription factor TFIIH holo complex	Cyclin-H	Homo sapiens (human)
CAK-ERCC2 complex	Cyclin-H	Homo sapiens (human)
transcription factor TFIIK complex	Cyclin-H	Homo sapiens (human)
nucleus	Cyclin-H	Homo sapiens (human)
nucleoplasm	Cyclin-A1	Homo sapiens (human)
cytosol	Cyclin-A1	Homo sapiens (human)
microtubule cytoskeleton	Cyclin-A1	Homo sapiens (human)
cyclin A1-CDK1 complex	Cyclin-A1	Homo sapiens (human)
cyclin A1-CDK2 complex	Cyclin-A1	Homo sapiens (human)
centrosome	Cyclin-A1	Homo sapiens (human)
cyclin A2-CDK2 complex	Cyclin-A1	Homo sapiens (human)
cytoplasm	Cyclin-A1	Homo sapiens (human)
nucleus	Cyclin-A1	Homo sapiens (human)
nuclear speck	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
cytoplasm	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
nucleus	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B3	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase beta-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (258)

Assay ID	Title	Year	Journal	Article
AID617779	Inhibition of PAK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617415	Cytotoxicity against human SKOV3 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1375009	Inhibition of recombinant human CDK9/cyclin T1 using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate after 90 mins by fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
AID272433	Activity of PKBalpha at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272418	Inhibition of CDK2/Cyclin E in presence of 100 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617724	Inhibition of MLK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617627	Inhibition of HIPK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617390	Cytotoxicity against human NCI-H23 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617295	Cytotoxicity against human SF295 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617626	Inhibition of HER4 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617704	Inhibition of IKK-epsilon assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617618	Inhibition of EPH-B3 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616322	Antiangiogenic activity against HUVEC cells assessed as inhibition of VEGF-induced cell migration-associated wound closure at >10 uM after 16 hrs by microscopic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272441	Cell cycle arrest in HT29 cells by accumulation at G0/G1 phase at 50 uM after 12 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1194736	Cytotoxicity against human K562 cells after 72 hrs by calcein AM staining-based fluorescence assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID617776	Inhibition of p38beta MAPK assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617398	Cytotoxicity against human RPMI8226 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617705	Inhibition of IR assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617777	Inhibition of p38delta MAPK assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1194738	Cytotoxicity against human RPMI8226 cells after 72 hrs by calcein AM staining-based fluorescence assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID616301	Inhibition of PKCzeta assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616303	Inhibition of PLK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617611	Inhibition of CDK9/cyclin T assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272417	Inhibition of CDK2/Cyclin E	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272443	Cell cycle arrest in HT29 cells by accumulation at G2/M phase at 50 uM after 12 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617785	Inhibition of PIM1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272467	Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 3 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617773	Inhibition of NEK6 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617400	Cytotoxicity against human LOXIMVI cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617707	Inhibition of IRR assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617782	Inhibition of PAK6 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617725	Inhibition of MLK3 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617516	Inhibition of CDK9-catalyzed RNA polymerase 2 phosphorylation at Ser2 in human HMEC1 cells after 2 hrs by immunoblotting	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617714	Inhibition of MAPKAP-K2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617720	Inhibition of MEKK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272423	Inhibition of CDK9/Cyclin T1 in presence of 100 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID616302	Inhibition of PKD1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617519	Inhibition of CDK9 by [33P]gamma-ATP incorporation assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617391	Cytotoxicity against human NCI-H322M cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272422	Inhibition of CDK7/Cyclin H in presence of 100 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272434	Activity of SAPK2-alpha at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272416	Viability of K562 cells at 100 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617771	Inhibition of MST4 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616311	Inhibition of SGK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272419	Inhibition of CDK1/Cyclin B in presence of 100 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617790	Inhibition of PKBbeta assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID723732	Stabilization of CDK2/Cyclin A (174 to 432 amino acid residues) (unknown origin) assessed as change in melting temperature at 20 uM by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID723735	Inhibition of CDK9/Cyclin T (1 to 330 amino acid residues) (unknown origin) by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID617423	Cytotoxicity against human SN12C cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272410	Antiproliferative activity against HOS cell line	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617394	Cytotoxicity against human CCRF-CEM cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272424	Activity of CDK9/Cyclin T1 at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1689408	Inhibition of human full-length N-terminal GST/His6-tagged CDK9 (1 to 372 residues)/His6-tagged Cyclin-T1 (1 to 726 residues) expressed in sf9 cells using (YSPTSPS)2KK peptide as substrate in presence of [gamma33P]ATP	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
AID617706	Inhibition of IRAK4 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617769	Inhibition of MSK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272469	Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 12 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617422	Cytotoxicity against human RXF393 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617620	Inhibition of ERK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616319	Inhibition of TTK assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617612	Inhibition of CK1delta assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617506	Antiangiogenic activity in VEGF-stimulated HMEC1 assessed as reduction in median length of tube at 20 uM after 16 hrs by photographic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617719	Inhibition of MARK4 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272466	Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617723	Inhibition of MKK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617625	Inhibition of GSK3b assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617709	Inhibition of JNK1A1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617393	Cytotoxicity against human NCI-H522 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617526	Inhibition of CAMK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617503	Antiangiogenic activity against HUVEC cells assessed as inhibition of VEGF-induced cell migration-associated wound closure after 16 hrs by microscopic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617502	Antiproliferative activity against HMEC1 cells assessed as decrease in cell viability at >50 uM within 72 hrs by calcein AM staining-based fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616310	Inhibition of S6K1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617300	Cytotoxicity against human COLO205 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617408	Cytotoxicity against human UACC62 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617419	Cytotoxicity against human A498 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617781	Inhibition of PAK5 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616321	Inhibition of YES1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617291	Cytotoxicity against human MCF7 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617722	Inhibition of MINK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272454	Decrease in pRb phosphorylation in MCF7 cells after 24 hrs at 50 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617716	Inhibition of MARK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617768	Inhibition of MNK2alpha assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617619	Inhibition of EPH-B4 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617298	Cytotoxicity against human SNB75 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617616	Inhibition of EPHA2 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617524	Inhibition of BRSK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617518	Inhibition of CDK7-catalyzed RNA polymerase 2 phosphorylation at Ser5 in human HMEC1 cells at 5 to 40 uM after 2 hrs by immunoblotting	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617416	Cytotoxicity against human DU145 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617418	Cytotoxicity against human 786-0 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616315	Inhibition of SYK assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272482	Increase in p53 expression level in MCF7 cells at 100 uM after 24 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272421	Inhibition of CDK4/Cyclin D1 in presence of 100 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617629	Inhibition of HIPK3 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617622	Inhibition of ERK8 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272455	Increase in p53 expression level in MCF7 cells at 50 uM after 24 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID616304	Inhibition of PRAK assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617783	Inhibition of PDK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617523	Inhibition of BRSK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617420	Cytotoxicity against human ACHN cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617302	Cytotoxicity against human HCT116 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617407	Cytotoxicity against human UACC257 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617304	Cytotoxicity against human HT-29 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272457	Reduction of RNA polymerase 2 CTD phosphorylation in MCF7 cells after 24 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617632	Inhibition of IGF-1R assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617509	Decrease in VEGF expression in human MCF7 cells at >10 uM after 24 hrs by sandwich ELISA	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617289	Cytotoxicity against human BT549 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617402	Cytotoxicity against human MALME-3M cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272460	Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 6 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617787	Inhibition of PIM3 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272425	Activity of CDK2/Cyclin E at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617613	Inhibition of CK2alpha assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272432	Activity of PKA at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617521	Inhibition of Aurora A assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617708	Inhibition of JAK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617789	Inhibition of PKBalpha assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617305	Cytotoxicity against human KM12 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616307	Inhibition of ROCK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617772	Inhibition of NEK2a assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617296	Cytotoxicity against human SF539 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1194741	Inhibition of CDK7/cyclin H (unknown origin) expressed in baculovirus infected Sf9 cells	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID617401	Cytotoxicity against human M14 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617711	Inhibition of JNK2alpha2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617412	Cytotoxicity against human OVCAR4 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617780	Inhibition of PAK4 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272465	Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 12 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617778	Inhibition of p38-gamma MAPK assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617395	Cytotoxicity against human HL-60(TB) cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617299	Cytotoxicity against human U251 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617309	Cytotoxicity against human HOP62 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272420	Inhibition of CDK2/Cyclin A in presence of 100 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID616308	Inhibition of RSK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617411	Cytotoxicity against human OVCAR3 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617770	Inhibition of MST2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID723734	Inhibition of CDK2/Cyclin A (174 to 432 amino acid residues) (unknown origin) by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID272431	Activity of P70S6K at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1194737	Cytotoxicity against human MCF7 cells after 72 hrs by calcein AM staining-based fluorescence assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID617775	Inhibition of p38alpha MAPK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272408	Inhibition of CDK2/Cyclin E in presence of 15 uM ATP	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617426	Antiproliferative activity against HUVEC cells assessed as decrease in cell viability at >50 uM within 72 hrs by calcein AM staining-based fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617712	Inhibition of JNK3alpha1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617425	Cytotoxicity against human UO31 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617292	Cytotoxicity against human MDA-MB-231 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617786	Inhibition of PIM2 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617520	Inhibition of AMPK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272430	Activity of MAPK1 at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID616410	Antiproliferative activity against HUVEC cells assessed as decrease in cell viability at 10 to 40 uM within 72 hrs by calcein AM staining-based fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272412	Antiproliferative activity against K562 cell line	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617710	Inhibition of Lck assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272440	Cell cycle arrest in HT29 cells by accumulation at G2/M phase at 50 uM after 6 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1375008	Inhibition of recombinant human CDK2/cyclin A using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate after 15 mins by fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
AID617294	Cytotoxicity against human SF268 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617307	Cytotoxicity against human A549 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616312	Inhibition of SmMLCK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272439	Cell cycle arrest in HT29 cells by accumulation at S phase at 50 uM after 6 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617389	Cytotoxicity against human NCI-H226 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617788	Inhibition of PKA assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616306	Inhibition of RIPK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272461	Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 12 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617512	Inhibition of TNF-alpha-induced Nuclear factor-kappa-B-mediated ICAM-1 expression in human HMEC1 cells after 24 hrs by FACS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617392	Cytotoxicity against human NCI-H460 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617409	Cytotoxicity against human IGROV1 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617414	Cytotoxicity against human OVCAR8 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617623	Inhibition of FGF-R1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617522	Inhibition of Aurora B assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617721	Inhibition of MELK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617791	Inhibition of PKCalpha assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617507	Antiangiogenic activity in VEGF-stimulated HMEC1 assessed as reduction in median length of tube at 40 uM after 16 hrs by photographic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617410	Cytotoxicity against human NCI/ADR-RES cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272483	Inhibition of P70S6K	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617397	Cytotoxicity against human MOLT4 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617624	Inhibition of GCK assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272409	Antiproliferative activity against MCF7 cell line	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617306	Cytotoxicity against human SW620 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272438	Cell cycle arrest in HT29 cells by accumulation at G0/G1 phase at 50 uM after 6 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617784	Inhibition of PHKG1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616411	Antiproliferative activity against HMEC1 cells assessed as decrease in cell viability at 10 to 40 uM within 72 hrs by calcein AM staining-based fluorescence assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616313	Inhibition of Src assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617774	Inhibition of NUAK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617718	Inhibition of MARK3 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617767	Inhibition of MNK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617405	Cytotoxicity against human SK-MEL-28 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617628	Inhibition of HIPK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617717	Inhibition of MARK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272436	Cell cycle arrest in HT29 cells by accumulation at S phase at 50 uM after 3 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1689407	Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate in presence of [gamma33P]ATP	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
AID616314	Inhibition of SRPK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616318	Inhibition of TrkA assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617630	Inhibition of CHK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617609	Inhibition of CAMKKbeta assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617417	Cytotoxicity against human PC3 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617310	Cytotoxicity against human HOP92 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617293	Cytotoxicity against human T47D cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272468	Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 6 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272463	Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 3 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272411	Antiproliferative activity against G361 cell line	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617413	Cytotoxicity against human OVCAR5 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617515	Inhibition of CDK9-catalyzed RNA polymerase 2 phosphorylation at Ser2 in human MCF7 cells after 2 hrs by immunoblotting	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272427	Activity of CHK1 at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272456	Increase in p21 WAF1 expression level in MCF7 cells at 50 uM after 24 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272453	Decrease in pRb phosphorylation in MCF7 cells after 24 hrs at 25 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1194742	Inhibition of CDK9/cyclin T1 (unknown origin) expressed in baculovirus infected Sf9 cells	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID272413	Viability of MCF7 cells at 100 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617505	Antiangiogenic activity in VEGF-stimulated HMEC1 assessed as reduction in total length of tube at 40 uM after 16 hrs by photographic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617631	Inhibition of CHK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617610	Inhibition of CDK2/cyclin A assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617396	Cytotoxicity against human K562 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617514	Inhibition of RNA synthesis in human HMEC1 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617614	Inhibition of CSK assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617715	Inhibition of MAPKAP-K3 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616320	Inhibition of VEGFR assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272459	Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 3 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617399	Cytotoxicity against human SR cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617308	Cytotoxicity against human EKVX cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617617	Inhibition of EPHA4 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617517	Inhibition of CDK7-catalyzed RNA polymerase 2 phosphorylation at Ser5 in human MCF7 cells at 5 to 40 uM after 2 hrs by immunoblotting	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617421	Cytotoxicity against human Caki1 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272415	Viability of G361 cells at 100 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617504	Antiangiogenic activity in VEGF-stimulated HMEC1 assessed as reduction in total length of tube at 20 uM after 16 hrs by photographic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616316	Inhibition of TAK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617621	Inhibition of ERK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616309	Inhibition of RSK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617297	Cytotoxicity against human SNB19 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617303	Cytotoxicity against human HCT15 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617424	Cytotoxicity against human TK10 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1194739	Inhibition of CDK1/cyclin B (unknown origin) expressed in baculovirus infected Sf9 cells	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID617703	Inhibition of IKK-beta assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617301	Cytotoxicity against human HCC2998 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1194740	Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected Sf9 cells	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID617403	Cytotoxicity against human MDA-MB-435 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272428	Activity of CK2 at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617511	Decrease in VEGF expression in human DU145 cells at >10 uM after 24 hrs by sandwich ELISA	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617404	Cytotoxicity against human SK-MEL-2 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616317	Inhibition of TBK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617525	Inhibition of BTK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617615	Inhibition of EF2K assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272464	Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM after 6 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617513	Inhibition of RNA synthesis in human MCF7 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1194735	Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
AID617406	Cytotoxicity against human SK-MEL-5 cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID617508	Antiangiogenic activity in VEGF-stimulated HMEC1 assessed as reduction in tube nodes after 16 hrs by photographic analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272462	Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617290	Cytotoxicity against human Hs 578T cells	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID616305	Inhibition of PRK2 assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID723733	Stabilization of CDK9/Cyclin T (1 to 330 amino acid residues) (unknown origin) assessed as change in melting temperature at 20 uM by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID617510	Decrease in VEGF expression in human MDA-MB-231 cells at >10 uM after 24 hrs by sandwich ELISA	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272458	Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 50 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272426	Activity of c-ABL at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272414	Viability of HOS cells at 100 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272442	Cell cycle arrest in HT29 cells by accumulation at S phase at 50 uM after 12 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID617713	Inhibition of LKB1 assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID272429	Activity of GSK3-beta at 10 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272435	Cell cycle arrest in HT29 cells by accumulation at G0/G1 phase at 50 uM after 3 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID272437	Cell cycle arrest in HT29 cells by accumulation at G2/M phase at 50 uM after 3 hrs	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID1800495	Kinase Selectivity from Article 10.1111/cbdd.12330: \\Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.\\	2014	Chemical biology & drug design, Oct, Volume: 84, Issue:4	Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
AID1796840	CDK Inhibition Assay from Article 10.1021/jm0605740: \\4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.\\	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	The selective P-TEFb inhibitor CAN508 targets angiogenesis.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2012	ACS chemical biology, May-18, Volume: 7, Issue:5	The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	8 (80.00)	24.3611
2020's	1 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.25	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.03	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.08	1
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.17	1	metal allergen; nickel group element atom; platinum group metal atom
staurosporine [no description available]	2.54	2	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.78	3	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cgp 74514a [no description available]	2.11	1
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.08	1	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.08	1	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor

Condition	Relationship Strength	Studies
Angiogenesis, Pathologic [description not available]	2.06	1
Kahler Disease [description not available]	2.1	1
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.1	1
Benign Neoplasms [description not available]	2.25	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.25	1

can 508

Description

Cross-References

Synonyms (53)

Bioavailability

Roles (4)

Drug Classes (4)

Protein Targets (18)

Inhibition Measurements

Biological Processes (186)

Molecular Functions (43)

Ceullar Components (62)

Bioassays (258)

Research

Studies (10)

Study Types

can 508

Description

Cross-References

Synonyms (53)

Bioavailability

Roles (4)

Drug Classes (4)

Protein Targets (18)

Inhibition Measurements

Biological Processes (186)

Molecular Functions (43)

Ceullar Components (62)

Bioassays (258)

Research

Studies (10)

Study Types

Related Drugs (9)

Related Conditions (5)